ASB Consultores LLC Sells 20 Shares of Eli Lilly and Company (NYSE:LLY)

ASB Consultores LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,125 shares of the company’s stock after selling 20 shares during the quarter. ASB Consultores LLC’s holdings in Eli Lilly and Company were worth $997,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Quent Capital LLC lifted its stake in shares of Eli Lilly and Company by 5.3% in the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after buying an additional 249 shares during the last quarter. Mutual Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 404.8% during the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after buying an additional 50,197 shares during the period. Whittier Trust Co. boosted its holdings in shares of Eli Lilly and Company by 52.2% during the 1st quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock worth $58,725,000 after buying an additional 25,877 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in Eli Lilly and Company by 155.1% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after buying an additional 12,004 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Bank of America lowered their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Stock Down 1.6 %

LLY opened at $806.14 on Tuesday. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The firm has a market cap of $765.28 billion, a price-to-earnings ratio of 87.15, a PEG ratio of 3.09 and a beta of 0.43. The firm’s 50-day simple moving average is $908.15 and its 200-day simple moving average is $867.39. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.